Search by Drug Name or NDC
NDC 50090-2093-04 SULINDAC 200 mg/1 Details
SULINDAC 200 mg/1
SULINDAC is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by A-S Medication Solutions. The primary component is SULINDAC.
MedlinePlus Drug Summary
Sulindac is used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints), rheumatoid arthritis (arthritis caused by swelling of the lining of the joints), and ankylosing spondylitis (arthritis that mainly affects the spine). Sulindac also is used to treat pain in the shoulder caused by bursitis (inflammation of a fluid-filled sac in the shoulder joint) and tendinitis (inflammation of the tissue that connects muscle to bone). It is also used to relieve gouty arthritis (attacks of severe joint pain and swelling caused by a build-up of certain substances in the joints). Sulindac is in a class of medications called NSAIDs. It works by stopping the body's production of a substance that causes pain, fever, and inflammation.
Related Packages: 50090-2093-04Last Updated: 02/05/2023
MedLinePlus Full Drug Details: Sulindac
Product Information
| NDC | 50090-2093 |
|---|---|
| Product ID | 50090-2093_7a81ebf2-98d8-4f0f-8fcf-5040fc34ae22 |
| Associated GPIs | 66100080000310 |
| GCN Sequence Number | 008366 |
| GCN Sequence Number Description | sulindac TABLET 200 MG ORAL |
| HIC3 | S2B |
| HIC3 Description | NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS |
| GCN | 35801 |
| HICL Sequence Number | 003729 |
| HICL Sequence Number Description | SULINDAC |
| Brand/Generic | Generic |
| Proprietary Name | SULINDAC |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | sulindac |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/1 |
| Substance Name | SULINDAC |
| Labeler Name | A-S Medication Solutions |
| Pharmaceutical Class | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA072051 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 50090-2093-04 (50090209304)
| NDC Package Code | 50090-2093-4 |
|---|---|
| Billing NDC | 50090209304 |
| Package | 60 TABLET in 1 BOTTLE (50090-2093-4) |
| Marketing Start Date | 2015-10-12 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |